Alacizumab pegol

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAlacizumab pegol
Drug Alias Namealacizumabum pegolum培戈-阿拉赛珠单抗培化阿珠单抗CDP-791
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsAngiogenesis inhibitors
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandRussian FederationHungary
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUcb PharmaImclone Systems Corp
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma

Other Information

ATC CodeN/A
Related LinksWikipedia